Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 17/20 | 0.51 |
| ▸ | CD63 | P08962 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | ROS1 | P08922 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.48 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20005722 | 0.89 | AURKA (0.65) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL15551811 | 0.87 | AURKA (0.52) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL15551918 | 0.83 | SYK (0.69) | SYKCD63JAK2 | |
| SCHEMBL15551735 | 0.81 | SYK (0.65) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL16848694 | 0.81 | SYK (0.53) | AURKASYKCD63JAK2 | |
| SCHEMBL5478247 | 0.80 | AURKA (0.61) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL15956956 | 0.79 | AURKA (0.50) | AURKASYKCD63 | |
| SCHEMBL2221438 | 0.79 | AURKA (0.60) | AURKASYKCD63BTK | |
| SCHEMBL2217499 | 0.79 | CCND3 (0.51) | AURKASYKCD63JAK2 | |
| SCHEMBL16848689 | 0.78 | SYK (0.71) | AURKASYKCD63JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | AURKA 794/4885SYK 1/4885CD63 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.